| Please type a plus sign (+ | Inside this tay The |
|----------------------------|---------------------|
| | 1 |

Substitute for form 1449A/B/FTO JAN 2 3 2004 &

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3

| | Compl te if Known | |
|------------------------|-------------------|---------------------------------------|
| Application Number | 10/706,265 | |
| Filing Date | November 12, 2003 | |
| First Named Inventor | Hwang | |
| Group Art Unit | Unassigned | |
| Examiner Name | Unassigned | |
| Attorney Docket Number | 224738 | · · · · · · · · · · · · · · · · · · · |

| | | | | U.S. PATENT DOCUMENTS | | |
|----------------------|-------------|---------------------------------|-----------|-------------------------------|------------------------|----------------------------|
| | | U.S. Patent Doc | cument | | | |
| Examiner Initials | Doc. No. | Application or Patent Number | Kind Code | Name of Patentee or Applicant | Date of Publication | Filing Date If Appropriate |
| OU | AA | 5,449,752 | | Fujii et al. | Sep. 12, 1995 | Apr. 29, 1992 |

| | | | | FORE | IGN PATENT DOCUMENTS | | | - |
|-------------------------|-------------|-------------------------|---------------------------------|--------------|---------------------------------------|---------------------|--|-------------|
| Foreign Patent Document | | Foreign Patent Document | | | | Translation | | |
| Examiner Initials | Doc. No. | Office | Application or Patent Number | Kind Code | Name of Patentee or Applicant | Date of Publication | Yes | No++ |
| 84 | AB | WO | 01/85196 | A2 | University of British Columbia et al. | Nov. 15, 2001 | | |
| NG | AC | WO | 99/47158 | A2 | University of British Columbia | Sep. 23, 1999 | <u> </u> | |
| 20 | AD | WO | 99/50461 | A1 | Northwest Biotherapeutics, Inc. | Oct. 7, 1999 | | |

| | | OTHER - NON PATENT LITERATURE DOCUMENTS | | |
|----------------------|-------------|--|------|-----------------|
| Examiner Initials | Doc. No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Yes | slation No*+ |
| NG | ΑE | ALON et al., "The Integrin VLA-4 Supports Tethering and Rolling in Flow on VCAM-1," J. Cell. Biol., Vol. 128 (6), pp. 1243-1253 (1995) | | |
| BB | AF | ARAKAKI et al., "T134, a Small-Molecule CXCR4 Inhibitor, Has No Cross-Drug Resistance with AMD3100, a CXCR4 Antagonist with a Different Structure," <i>J. Virol.</i> , Vol. 73 (2), pp. 1719-1723 (1999) | | |
| | AG | BALKWILL, "Chemokine biology in cancer," Semin. Immunol., Vol. 15, pp. 49-55 (2003) | | <u> </u> |
| 814 | AH | CLARK et al., "Genomic analysis of metastasis reveals an essential role for RhoC," Nature, Vol. 406, pp. 532-535 (2000) | | |
| 8 V | AI | CLERCQ et al., "Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists," Antivir. Chem. Chemother., Vol. 12 (Supp. 1), pp. 19-31 (2001) | | · . |
| Din | AJ | COHN-CEDERMARK et al., "Metastatic Patterns, Clinical Outcome, and Malignant Phenotype in Malignant Cutaneous Melanoma," <i>Acta Oncl.</i> , Vol. 38 (5), pp. 549-557 (1999) | | |
| 8-6 | AK | COIT et al., "Prognostic Factors in Patients With Melanoma Metastatic to Axillary or Inguinal Lymph Nodes," <i>Ann Surg.</i> , Vol. 214 (5), 627-636 (1991) | | |
| 84 | ΑĹ | CONSTANTIN et al., "Chemokines Trigger Immediate β2 Integrin Affinity and Mobility Changes: Differential Regulation and Roles in Lymphocyte Arrest under Flow," Immunity, Vol. 13, pp. 759-769 (2000) | | |
| S ba | AM | DORANZ et al., "Safe Use of the CXCR4 Inhibitor ALX40-4C in Humans," AIDS Res. Hum. Retroviruses, Vol. 17 (6), pp. 475-486 (2001) | ···· | |
| DB | AN | ENGERS et al., "Mechanisms of tumor metastasis: cell biological aspects and clinical implications," J. Cancer Res. Clin. Oncol., Vol. 126, pp. 682-692 (2000) | | |
| 8 | AO | FRIES et al., "Expression of VCAM-1 and E-Selectin in an in Vivo Model of Endothelial Activation," Am. J. Pathol., Vol. 143 (3), pp.725-737 (1993) | | <u> </u> |
| 84 | AP | GEMINDER et al., "A Possible Role for CXCR4 and Its Ligand, the CXC Chemokine Stromal Cell-Derived Factor-1, in the Development of Bone Marrow Metastases in Neuroblastoma ¹ ," J. Immunol., Vol. 167, pp. 4747-4757 (2001) | | - |
| 84 | AQ | GIAVAZZI et al., "Rolling and Adhesion of Human Tumor Cells on Vascular Endothelium under Physiological Flow Conditions," <i>J. Clin. Invest.</i> , Vol. 92, pp. 3038-3044 (1993) | | |

| Examiner Signature | Date Considered Cl. 1 |
|--------------------|-----------------------|
| 1 8 Commit | 5(11/65 |
| | |

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise

| Please type a pl | us sign (+) inside this b | TO PE | | | |
|-------------------|--|------------|---------|------------------------|-------------------|
| | | | 3/ | | Complete if Known |
| Substitute for fo | THE THE PROPERTY OF THE PROPER | 2 3 2004 | 00 | Application Number | 10/706,265 |
| INFO | ORMATION | DISC | SHE | Filing Date | November 12, 2003 |
| STA | TEMENTE | | E ICANT | First Named Inventor | Hwang |
| 314 | I EINIEIN KE | RADIS | PLICANI | Group Art Unit | Unassigned |
| | (Use as many she | ets as nec | essary) | Examiner Name | Unassigned |
| Sheet | 2 | of | 3 | Attorney Docket Number | 224738 |

* *

| Examiner | Doc. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item | | | | | | | |
|----------|------|--|-------------|------|--|--|--|--|--|
| Initials | No. | (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Yes | No*1 | | | | | |
| ัชน | AR | HART et al., "Role of Organ Selectivity in the Determination of Metastatic Patterns of B16 Melanoma ¹ ," Cancer Res., Vol. 40, pp. 2281-2287 (1980) | | | | | | | |
| NG | AS | HENDRIX et al., "Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers," <i>Antimicrob., Agents Chemother.</i> , Vol. 44 (6), pp. 1667-1673 (2000) | | | | | | | |
| NB | ΑТ | KIJIMA et al., "Regulation of Cellular Proliferation, Cytoskeletal Function, and Signal Transduction through CXCR4 and c-Kit in Small Cell Lung Cancer Cells," Cancer Res., Vol. 62, pp. 6304-6311 (2002) | | | | | | | |
| NG. | AU | KOSHIBA et al., "Expression of Stromal Cell-derived Factor 1 and CXCR4 Ligand Receptor System in Pancreatic Cancer: A Possible Role for Tumor Progression," Clin. Cancer Res., Vol. 6, pp. 3530-3535 (2000) | | | | | | | |
| 9 U | AV | LANGLEY et al., "Endothelial Expression of Vascular Cell Adhesion Molecule-1 Correlates with Metastatic Pattern in Spontaneous Melanoma," <i>Microcirculation</i> , Vol. 8, pp. 335-345 (2001) | | | | | | | |
| NB | AW | LAWRENCE et al., "Effect of Flow on Polymorphonuclear Leukocyte/Endothelial Cell Adhesion," <i>Blood</i> , Vol. 70 (5), pp. 1284-1290 (1987) | | | | | | | |
| 8 U | AX | LAWRENCE et al., "Neutrophilis Roll on E-Selectin ¹ ," J.Immunol., Vol. 151 (11), pp. 6338-6346 (1993) | | | | | | | |
| 8·N | AY | LIBURA et al., "CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion," <i>Blood</i> , Vol. 100 (7), pp. 2597-2606 (2002) | | | | | | | |
| 84 | ΑZ | LOCATI et al., "Chemokines and Chemokine Receptors: Biology and Clinical Relevance in Inflammation and AIDS ¹ ," <i>Annu. Rev. Med.</i> , Vol. 50, pp. 425-440 (1999) | | | | | | | |
| 84 | ВА | MAKI et al., "CCR6 Colocalizes with CD18 and Enhances Adhesion to Activated Endothelial Cells in CCR6-Transduced Jurkat T Cells," <i>J. Immunol.</i> , Vol. 169, pp. 2346-2353 (2002) | | - | | | | | |
| Ø N | BB | MASHINO et al., "Expression of Chemokine Receptor CCR7 Is Associated with Lymph Node Metastasis of Gastric Carcinoma ¹ ," Cancer Res., Vol. 62, pp. 2937-2941 (2002) | • | | | | | | |
| 8) N | BC | MENTER et al., "Human melanoma integrins contribute to arrest and stabilization potential while flowing over extracellular matrix," <i>Immunol. Cell Biol.</i> , Vol. 73, pp. 575-583 (1995) | | | | | | | |
| 85.11 | BD | MIDDLETON et al., "Transcytosis and Surface Presentation of IL-8 by Venular Endothelial Cells," Cell, Vol. 91, pp. 385-395 (1997) | | | | | | | |
| NB | BE | MÜLLER et al., "Involvement of chemokine receptors in breast cancer metastasis," Nature, Vol. 410, pp. 50-56 (2001) | | | | | | | |
| 8 M | 8F | MURAKAMI et al., "Expression of CXC Chemokine Receptor-4 Enhances the Pulmonary Metastatic Potential of Murine B16 Melanoma Cells ¹ ," Cancer Res., Vol. 62, pp. 7328-7334 (2002) | | | | | | | |
| DG | BG | MURAKAMI et al., "A Small Molecule CXCR4 Inhibitor that Blocks T Cell Line-tropic HIV-1 Infection," J. Exp. Med., Vol. 186 (8), pp. 1389-1393 (1997) | | | | | | | |
| 84 | вн | MURPHY et al., "Chemokines and the Molecular Basis of Cancer Metastasis," N. Engl. J. Med., Vol. 345 (11), pp. 833-835 (2001) | | | | | | | |
| 24 | ВІ | OKAHARA et al., "Involvement of Very Late Activation Antigen 4 (VLA-4) and Vascular Cell Adhesion Molecule 1 (VCAM-1) in Tumor Necrosis Factor α Enhancement of Experimental Metastasis," Cancer Res., Vol. 54, pp. 3233-3236 (1994) | | | | | | | |

| Fig. 1. Ci | |
|--------------------|-------------------------------------|
| Examiner Signature | Date Considered 5 11 103 |
| 1 cd blees | Date Collaideled 2 (11 (\sigma') |
| | () |
| | |

| точно турс в раз | S sign (*) histor dus co. | | | • | | |
|------------------|--|---------|------------------------|------------------------|-------------------|---|
| 0, 40 | Complete if Known | | | | | |
| | rm 1449A/B/PTO | | 2006 | Application Number | 10/706,265 | |
| INFO | RMATION | DIM O | I OSLERE | Filing Date | November 12, 2003 | |
| STA | INFORMATION DISCLOSURE STATEMENT BY APPLICANT | PLICANT | First Named Inventor | Hwang | | |
| 314 | I CINICIA I DA | | TENESTINI TENESTINI | Group Art Unit | Unassigned | · |
| | (Use as many sheet | s as ne | cessary) | Examiner Name | Unassigned | |
| Sheet | 3 | of | 3 | Attorney Docket Number | 224738 | |

| | | OTHER - NON PATENT LITERATURE DOCUMENTS | | |
|----------------------|-------------|--|---------------|--------------|
| Examiner Initials | Doc. No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Tran: Yes | No* |
| | ВЈ | ROBLEDO et al., "Expression of Functional Chemokine Recentors CXCR3 and CXCR4 | | |
| 81 | ВК | on Human Melanoma Cells," J. Biol. Chem., Vol. 276 (48), pp. 45098-45105 (2001) | | |
| L | ВK | SALVUCCI et al., "Regulation of endothelial cell branching morphogenesis by | | |
| 84 | | endogenous chemokine stromal-derived factor-1," <i>Blood</i> , Vol. 99 (8), pp. 2703-2711 (2002) | | ļ |
| NB | BL | SEFTOR et al., "Molecular role(s) for integrins in human melanoma invasion," Cancer Metastasis Rev., Vol. 18, pp. 359-375 (1999) | | |
| 84 | ВМ | SHIMAOKA et al., "Therapeutic Antagonists and Conformational Regulation of Integrin Function," Nat. Rev. Drug Discovery, Vol. 2, pp. 703-716 (2003) | | |
| 84 | BN | SKOBE et al., "Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis," <i>Nat. Med.</i> , Vol. 7 (2), pp. 192-198 (2001) | | |
| 864 | ВО | STACKER et al., "VEGF-D promotes the metastatic spread of tumor cells via the lymphatics," Nat. Med., Vol. 7 (2), pp. 186-191 (2001) | | |
| | ВР | TAICHMAN et al., "Use of the Stromal Cell-derived Factor-1/CXCR4 Pathway in | | - |
| 81 | | Prostate Cancer Metastasis to Bone ¹ ," Cancer Res., Vol. 62, pp. 1832-1837 (2002) | | |
| | BQ | AMAMURA et al., "A Low-Molecular-Weight Inhibitor against the Chemokine Recentor | | |
| l | | CXCR4: A Strong Anti-HIV Peptide T140," Biochem. Biophys. Res. Commun., Vol. 253. | | ٠. |
| Sh | | pp. 877-882 (1998) | | 1 |
| | BR | VIDAL-VANACLOCHA et al., "IL-18 regulates IL-1 β-dependent hepatic melanoma | | |
| | 1 | metastasis via vascular cell adhesion molecule-1," <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 97 | ٠. | l |
| -81 | 155 | (2), pp. 734-739 (2000) | | <u>'</u> |
| | BS | WILEY et al., "Expression of CC Chemokine Receptor-7 and Regional Lymph Node | | |
| 85 H | | Metastasis of B16 Murine Melanoma," J. Natl. Cancer Inst., Vol. 93, pp. 1638-1643 (2001) | | |
| S | ВТ | WONG et al., "Chemokines: attractive mediators of the immune response," Semin. Immunol., Vol. 15, pp. 5-14 (2003) | | |
| 8V | ΒU | WOODHOUSE et al., "General Mechanisms of Metastasis," Cancer, Vol. 80, pp. 1529-1537 (1997) | · · | |
| - V | | 1337 (1337) | | |
| | | | | |
| | | | | |
| | | | | · · |
| | _ | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| F | | | | |
| | | | | |
| | | | | |

Examin r Signature 8 1/1/25